The chain of identity that defines cell and gene therapy operations
An autologous cell therapy dose is not a SKU in the traditional sense. It is a manufactured product made for a single patient, from that patient's own starting material. The chain runs from apheresis at a treatment center, through transport to the manufacturing facility, through process steps, through quality release, through return transport, to infusion. At every step, the identity has to be preserved and traceable.
An allogeneic dose comes from a different chain. A master cell bank derived from a screened donor. Working cell banks expanded from the master. Final product lots manufactured from the working banks. Doses dispensed to patients. The chain is longer but the principle is the same: every dose has to trace back through the lineage to the donor.
NetSuite, configured for cell and gene therapy, treats the lot as the unit of inventory, the unit of cost, and the unit of traceability. Oracle NetSuite's Life Sciences ERP documentation notes that integrated monitoring tools track batches, lots, and inventory from supplier to patient, providing full lot genealogy for rapid, accurate, and complete recalls. Archer's cell and gene therapy industry page describes the configuration that makes the platform work for the modality.
In autologous therapy, the patient is the starting material and the destination. The chain has to be preserved end to end, and the ERP is the record of it.
Autologous: lot of one configuration
For autologous therapy, the manufactured batch produces one dose for one patient. Standard inventory logic (multiple units per SKU) breaks down. The configuration treats the lot as the primary identifier.
Item record structure
The item record is the therapy program, not the dose. The dose is the lot. Each lot carries:
- Patient identifier as an encrypted custom field
- Apheresis reference: date, time, collection site
- Manufacturing batch record reference
- Quality release status
- Shipping condition data (temperature, time in transit)
- Infusion confirmation, when received from the treatment center
Identity protection
Direct patient identifiers (name, MRN, date of birth) are stored only in fields with restricted role-based access. Operational staff see the encrypted token: a manufacturing reference number that links to identity through a controlled lookup. This protects the patient under HIPAA while preserving traceability for authorized roles.
Chain of custody events
Every movement of the autologous product posts to the lot transaction history. Archer's 3PL Integration handles the data flow from the collection site, the courier, the manufacturing facility, and the treatment center. Time stamps, location, responsible party, and condition data all live in NetSuite, not in a separate logistics system.
Allogeneic: lineage tracking from master cell bank to dose
For allogeneic therapy, the configuration extends NetSuite lot tracking to support lineage depth.
| Level | What it represents | Linked to |
|---|---|---|
| Master cell bank lot | Original cell stock derived from screened donor | Donor reference (encrypted), screening records, IND or BLA reference |
| Working cell bank lot | Expanded from master cell bank for manufacturing use | Parent master cell bank lot |
| Drug substance lot | Cellular product manufactured from working cell bank | Parent working cell bank lot, batch record |
| Drug product lot | Formulated, filled, and labeled final product | Parent drug substance lot |
| Patient dose | Individual dose dispensed and administered | Parent drug product lot, patient identifier |
The full lineage is queryable from any level. A regulatory recall or quality investigation can identify every patient who received product from a specific master cell bank in a single query.
Cost accounting on small batches
Standard costing assumes a denominator larger than 1. For autologous, the denominator is 1. For allogeneic, the denominator can be small or variable depending on yield. Both require actual costing at the lot level.
Configuration approach:
- Raw materials, direct labor, and overhead are collected against the manufacturing order for the specific lot.
- Indirect labor and facility overhead allocate to lots based on a defined methodology (typically labor hours or batch days).
- Batch failure is captured as a discrete event with a cost variance treatment that distinguishes recoverable from non-recoverable spend.
- Yield variance is tracked separately from cost variance. A low-yield successful batch is different from a failed batch.
The result is a defensible per-lot cost that supports both internal pricing decisions and external reporting under ASC 606.
Certificate of analysis generation
Every released lot needs a certificate of analysis: a formal document attesting that the lot meets release specifications. For cell and gene therapy, the CoA includes identity, purity, potency, sterility, viability, and lot-specific manufacturing parameters.
The CoA is generated from NetSuite, not from a separate document system. The configuration:
- Quality test results post to the lot record from the LIMS integration or manual entry
- A configured document template assembles the CoA: header with product and lot identifiers, test results table, manufacturing parameters, release statement
- Quality unit reviews and approves the CoA through Approvals App with electronic signature per 21 CFR Part 11
- The signed CoA attaches to the lot record and to the customer shipment
The CoA is reproducible from the lot record at any time. If a customer or regulator asks for the CoA on a 3-year-old lot, the query takes seconds.
IND to BLA transition: what changes
The lot tracking configuration that works at IND stage continues at BLA stage with minor adjustments. The substantive changes are in cost accounting and revenue recognition, not in traceability. Per FDA cellular and gene therapy guidance, the traceability requirements that apply during clinical development continue post-approval. The chain of identity is part of the regulatory commitment, not a clinical-stage practice that ends at launch.
For Archer engagements, the implementation is designed for both stages from go-live. The cell and gene therapy configuration handles clinical and commercial operating modes without rebuild at transition.
Related on archerinsights.com
- Cell and gene therapy. Archer's full configuration for autologous and allogeneic programs.
- NetSuite for cell and gene therapy hub. Foundation configuration for CGT companies.
- Biotech and pharmaceuticals industry page. Clinical and commercial-stage configuration.
- Quality Management System. GMP and Part 11 compliant quality workflows.
- 3PL Integration. Chain of custody and treatment center handoff data flow.
- Contract Lifecycle Management. Outcome-based contract and milestone tracking.